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Abstract
Viridicatumtoxin (1) is a tetracycline-like fungal meroterpenoid with a unique, fused spirobicyclic 
ring system. Puzzlingly, no dedicated terpene cyclase is found in the gene cluster identified in 
Penicillium aethiopicum. The two cytochrome P450 enzymes VrtE and VrtK in the vrt gene 
cluster were shown to catalyze C5-hydroxylation and spirobicyclic ring formation, respectively. 
Feeding of acyclic previridicatumtoxin (2) to Saccharomyces cerevisiae expressing VrtK 
confirmed that VrtK is the sole enzyme required for cyclization of the geranyl moiety. Thus, VrtK 
is the first example of a P450 that can catalyze terpene cyclization, most likely via the initial 
oxidation of C17 to an allylic carbocation. Quantum chemical modeling revealed a possible new 
tertiary carbocation intermediate E that forms after the allylic carbocation formation. The 
intermediate E can readily undergo concerted 1,2-alkyl shift/1,3-hydride shift, either 
spontaneously or further aided by the active site configuration of VrtK, followed by C7 Friedel-
Crafts alkylation to afford 1,. The most likely stereochemical course of the reaction was proposed 
based on the results of our computations.
Viridicatumtoxin (1) is a fungal meroterpenoid consists of an unusual monoterpene-derived 
spirobicyclic ring fused to an anhydrotetra-cycline-like, 2-carboxamide naphthacenedione 
scaffold.1 1 and its derivative viridicatumtoxin B exhibits anti-MRSA activity.2 Compound 
1 along with a C2 acetyl analog, spirohexaline, have been demonstrated to inhibit the growth 
of bacteria by inhibition of the undecaprenyl diphosphate synthase,3 a potential new target 
for antibiotic development. The vrt gene cluster for the biosynthesis of 1 was identified in 
Penicilium aethiopicum using genome sequencing.4 More recently, the prenyltransferase 
VrtC responsible for the Friedel-Crafts alkylation at C6 of the naphthacenedione with 
geranyl diphosphate (GPP) to afford previridicatumtoxin (2) was characterized in detail.5 
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However, the mechanism for the formation of the spirobicyclic ring (Scheme 1) that is 
further fused to C7 of the naphthacene core, especially in the absence of a dedicated terpene 
cyclase encoded in the gene cluster, remains intriguing. The spirobicyclic system with a 
hindered C15 quaternary carbon center, is a striking structural features that sparked a recent 
total synthesis effort and led to structure reassignment of viridicatumtoxin B as a quinone 
derivative of 1.6
Our initial hypothesis proposed that cyclization of the geranyl substituent of 2 could begin 
with the addition of a hydroxyl at the allylic C17 position, followed by protonation of the 
hydroxyl and formation of an allylic cation accompanied by loss of water.4 The carbocation 
can then initiate the cascade of cyclization reaction. We reasoned that the same enzyme that 
performs the C17 hydroxylation step may also orient the geranyl chain in a configuration 
that leads to the regiospecific C15-C20 and C7-C15 cyclization events, thereby serving the 
additional function as a cryptic terpene cyclase. Cyclization of terpenes catalyzed by 
oxygenases is exceptionally rare, one example being the oxidative cyclization of the 
monoterpene group of cannabigerolic-acid by a berberine bridge enzyme-like flavin-
dependent monooxygenase.7
As cytochrome P450 monooxygenases are likely candidates to catalyze the proposed C17 
allylic oxidation, we began the search by genetically deleting each of the two genes 
encoding P450 monooxygenase (vrtE and vrtK) in the vrt gene cluster in P. aethiopicum. 
Using a double homologous gene targeting approach described previously,4 vrtE was 
deleted in the P. aethiopicum ΔgsfA strain. The ΔgsfA mutant was used as a background 
strain due to abolishment of griseofulvin biosynthesis, which provides a cleaner chemotype 
for metabolite analysis. The ΔvrtE strain lost the production of 1, but accumulated a new 
naphthacenedione intermediate 3 (m/z 402 [M+H]+) (Figure 1 and S7). The compound was 
subsequently isolated and characterized by 1D and 2D-NMR. The NMR spectra of 3 
comparable to that reported previously for anthrotainin9 and 5-hydroxyanthrotainin,5 except 
the absence of the 8-O-methyl signal. A 1,3-keto-enol tautomer can also be detected in 
DMSO-d6 (Table S2). Hence, the structure of 3 was assigned as the 8-O-desmethyl 
derivative of anthrotainin9 as shown in Figure 1D. The elucidation of the structure of 3 
implies that the function of VrtE is to perform a single hydroxylation at C5 of 3. 3 is the 
expected product of the non-reducing PKS VrtA, which functions in collaboration with the 
auxiliary enzymes VrtG (dimanganese-containing Claisen Cyclase) and VrtH (C12a 
monooxygenase).8 The accumulation of 3 suggests downstream enzymes, including 8-O-
methyltransferase (VrtD) and prenyltransferase (VrtC) require the installation of the C5-OH 
by VrtE for substrate recognition.
On the other hand, the vrtK deletion in the P. aethiopicum ΔgsfA strain abolished the 
production of 1 but accumulated a new intermediate 2 with a m/z 550 [M+H-H2O]+ and m/z 
568 [M+H]+ in the culture extract (Figure 1 and S7). Comparing 2 with a standard shows 
that it is the uncyclized meroterpenoid 2, which is the product of the VrtC-catalyzed 
geranylation as shown in the previous study (Table S3).5 This confirms our hypothesis that 
VrtK is the P450 enzyme that initiates the cyclization of the spirobicyclic ring that 
eventually transforms 2 into 1. However, the genetic result alone does not exclude the 
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possibility that other enzymes in P. aethiopicum may be involved in the cyclization step 
following oxidation of the terpene moiety in 2.
To further investigate the role of VrtK, we expressed VrtK heterologously in Saccharomyces 
cerevisiae BJ5464. VrtK was cloned into pESC-leu2d-AtCPR vector containing the A. 
terreus cytochrome P450 reductase (AtCPR) gene under the regulation of Gal10 promoter. 
AtCPR has been demonstrated to be able to perform the coupled reduction of fungal P450 in 
S. cerevisiae for biotransformations.10 The activity of VrtK was examined by feeding 1 mg 
of substrate 2 to 100 mL of galactose-induced yeast culture expressing AtCPR and VrtK. A 
slight conversion of 2 to 1 can be observed after 24 hours of incubation, while no conversion 
was observed in the control yeast culture expressing only AtCPR. Near complete 
biotransformation of 2 to 1 was obtained when 2 was fed to a culture with higher density 
yeast cells prepared by concentrating 500 mL of culture to 100 mL (Figure 2). No C17 
hydroxylated derivative or other intermediate derived from 2 can be detected under all tested 
culturing conditions. The relatively slower conversion rate and the requirement of 
concentrated yeast cells for the biotransformation could be attributed to poor expression 
level of the VrtK in S. cerevisiae, the poor solubility of the substrate 2, and/or the poor entry 
of 2 into the yeast cells. To test if VrtK could cyclize analogs of 2 with a dimethylallyl 
moiety, the yeast culture expressing VrtK was fed with the dimethylallyl analog of 
TAN1612,5 but the substrate cannot be converted by VrtK under the same conditions 
(Figure S8).
The successful biotransformation of 2 to 1 supports the proposal that VrtK is the sole 
enzyme required for the cyclization of the geranyl moiety of 2 to the spirobicyclic ring in 1. 
The cyclization could be initiated by C17-hydroxylation via the typical hydrogen 
abstraction/oxygen rebound mechanism followed by ionization to the allylic cation 
intermediate A in the presence of the Lewis acidic heme iron (Scheme 2). A similar 
mechanism is observed for the P450 enzyme LovA involved in lovastatin biosynthesis, 
whereby an allylic alcohol is first formed then dehydrates, presumably via an allylic cation 
intermediate, to give monacolin L by proton loss.10a However, the absence of a C-17 
hydroxylated intermediate in the biotransformation assay suggests that VrtK may 
alternatively initiate the cyclization cascade via dehydrogenation of the allylic C17 to give a 
carbon radical followed by electron transfer to the iron-heme center to form the 
corresponding carbocation A (Scheme 2). Such a mechanism has been proposed for P450-
catalyzed desaturation reactions,11 e.g. alkyl dehydrogenation/hydroxylation of 
capsaicinoids.12 Indeed, a homology search of VrtK indicates that the enzyme shares 
significant protein sequence similarity (42% identity) to the versicolorin desaturase VerB 
(StcL) in the aflatoxin pathway, which catalyzes desaturation of the bisfuran ring system of 
versicolorin B to afford versicolorin A.13
The mechanism of the geranyl cyclization was previously probed by feeding of [13C,2H] 
labeled mevalonates.14 The observation that two 2H atoms are present at C19 of 1 derived 
from feeding of (3RS)-[5-13C,4-2H2]mevalonolactone, provided evidence for a 1,3-hydride 
shift from C15 to C19 (corresponds to C2 and C6 of geranyl diphosphate) during the 
conversion of 2 to 1 (Figure 3). It was proposed that formation of the spirobicyclic ring is 
proceeded by the attack of C20 on C15 (Figure 3, A→B) followed by a 1,3-hydride shift to 
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give the intermediate C. With the new biosynthetic insight, we sought to further our 
understanding of the mechanism of the cyclization reaction using computational quantum 
chemistry (mPW1PW91/6-31+G(d,p)//B3LYP/6-31+G(d,p), MPWB1K/6-31+G(d,p)//
B3LYP/6-31+G(d,p) M06-2X/6-31+G(d,p)//B3LYP/6-31+G(d,p) and B3LYP/6-31+G(d,p)/
6-31+G(d,p)//B3LYP/6-31+G(d,p) calculations; see Supporting Information for details and 
references).15 The model system shown in Figure 3 (box) was utilized to examine the 
inherent reactivity of putative carbocations (i.e., in the absence of the enzyme).
On the basis of the results of our calculations, we propose that the mechanism postulated by 
Horak et al. (Figure 3; orange path) be revised to a mechanism involving tertiary carbocation 
intermediate E (Figure 3, green) instead of secondary carbocation B,14 which was found not 
to be a minimum on the potential energy surface. Cation E is predicted to undergo ring 
expansion (1,2-alkyl shift) and 1,3-hydride shift through a single step reaction in which 
these two events are combined asynchronously.16
We examined variations on this pathway, differing in the conformations/configurations of 
the intermediates involved, but not in the configuration of viridicatumtoxin produced. The 
transition state structures involved in each of these four pathways are shown in Figure 4. We 
predict that all four paths are energetically accessible (see Supporting Information for all 
energies), but path 1 (Figure 5) does not require any conformational changes of 
intermediates. Thus, if the reactant is preorganized by VrtK into the conformation shown in 
Figure 5 for path 1, rearrangement of the active site structure to accommodate 
conformational changes of the substrate is not required.17 The overall barrier for path 1 is 
predicted to be <10 kcal/mol. For the rearrangement to follow path 2, 3 or 4, the formation 
of additional intermediates and/or substantial changes to substrate conformation during the 
cyclization/rearrangement cascade are predicted to be necessary. Thus, it is likely that the 
active site of VrtK provides a structural template that chaperones the reactive carbocationic 
intermediate A to D via path 1 in such a way that allows its inherent reactivity to be 
expressed while reducing the energy barrier for cyclization further.15,16
To the best our knowledge, this is the first report of a cytochrome P450 enzyme that is 
capable of catalyzing terpene cyclization. Interestingly, the P450 albaflavenone 
monooxygenase from Streptomyces coelicolor A3 was recently discovered to contain a 
moonlighting class I terpene synthase active site and can convert farnesyl diphosphate to 
farnesene isomers in addition to its original function in oxidation of epi-isozizaene to 
albaflavenone.18 In contrast to class I terpene cyclases, which generate an carbocation by 
ionization of the allylic diphosphate ester, class II terpene cyclases promote cyclization by 
protonation of a terminal double bond.19 VrtK is similar to class II terpene cyclases in that it 
does not act on a diphosphate terpene substrate; however, a carbocation is proposed to be 
generated by oxidation of an allylic carbon (C17), corresponding to C4 of geranyl moiety. 
This discovery expands our knowledge of the catalytic diversity of cytochrome P450 
enzymes and provides new insights into meroterpenoid biosynthesis in fungi.
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Deletion of the individual P450 genes in the vrt gene cluster in P. aethiopicum. LCMS 
analyses of extracts from (A)ΔgsfA; (B) ΔgsfA/ΔvrtE; (C) ΔgsfA/ΔvrtK; (D) Structure of 3.
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Biotransformation of 2 to 1 by S. cerevisiae BJ5464 co-expressing AtCPR and VrtK. The 
control (top) yeast harbors the pESC-leu2d-AtCPR plasmid without vrtK.
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Proposed mechanisms for the formation of 1. Previously proposed mechanism via secondary 
carbocation B (in black and orange path). Newly proposed mechanism based on the results 
of quantum chemical calculations (black and green path). Box: model systems for 
computational modeling. HΔ and ● indicate the labeling of 2H and 13C on the geranyl 
moiety from (3RS)-[5-13C,4-2H2]-mevalonolactone.13
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Different conformations/configurations of transition state structures for reaction steps along 
the black/green pathway shown in Figure 3.
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Reaction energy diagram (M06-2X/6-31+G(d,p)//B3LYP/6-31+G(d,p)) for path 1 (Figure 
4, R=OH); relative energies (kcal/mol) and selected distances (Å) are shown.
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Spirocyclization of the geranyl moeity of 2 to afford 1.
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Proposed C17 carbocation formation by VrtK.
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